1-3 of 3
Joel Victor
Close
Sort by
Journal Articles

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Ioannis Mantzaris, Mendel Goldfinger, Nishi Shah, Annemarie Munoz, Aradhika Dhawan, Nicole Chambers, Karen Fehn, Joel Victor, Aditi Shastri, Kira Gritsman, Noah Kornblum, Alejandro Sica, Dennis L Cooper, Amit Verma, Mimi Kim, Ulrich Steidl, Eric J Feldman, Marina Y. Konopleva
Journal: Blood
Blood (2023) 142 (Supplement 1): 4257.
https://doi.org/10.1182/blood-2023-188176
Published: 2023
Journal Articles

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Mendel Goldfinger, Abigail Epstein, Ioannis Mantzaris, Aditi Shastri, Kira Gritsman, Noah Kornblum, Alejandro Sica, Nishi Shah, Dennis L Cooper, Swati Goel, David Levitz, Lauren Shapiro, Kith Pradhan, Annemarie Munoz, Monica Comas, Karen Fehn, Aradhika Dhawan, Joel Victor, Yogen Saunthararajah, Amit Verma, Marina Y. Konopleva, Eric J Feldman
Journal: Blood
Blood (2023) 142 (Supplement 1): 4258.
https://doi.org/10.1182/blood-2023-185379
Published: 2023
Journal Articles

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay

Ioannis Mantzaris, Mendel Goldfinger, David Levitz, Kateryna Fedorov, Karen Fehn, Nicole Chambers, Anne Munoz, Aradhika Dhawan, Joel Victor, Nishi Shah, Aditi Shastri, Noah Kornblum, R. Alejandro Sica, Kira Gritsman, Dennis Cooper, Mimi Kim, Evripidis Gavathiotis, Marina Konopleva, Amit Verma, Eric J. Feldman, Ulrich G. Steidl
Journal: Blood
Blood (2022) 140 (Supplement 1): 3360–3361.
https://doi.org/10.1182/blood-2022-167849
Published: 2022